Systematic Review of the Efficacy and Safety of Lenvatinib in Various Solid Tumors

Conclusions Lenvatinib in various solid tumors can prolong OS and disease PFS of patients, improve the clinical benefit rate and improve the quality of life of patients. At the same time, there is a certain incidence of adverse events, and symptomatic intervention should be given in clinical medication.PMID:38627024 | DOI:10.1080/08923973.2024.2344153
Source: Immunopharmacology and Immunotoxicology - Category: Allergy & Immunology Authors: Source Type: research